We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App





Portable Instrument Combines Fluorescence Reader and Microfluidic Chip for Detection of SARS-CoV-2 in Saliva

By LabMedica International staff writers
Posted on 23 Feb 2022
Print article
Image: Small form factor flow virometer for SARS-CoV-2 (Photo courtesy of ICFO)
Image: Small form factor flow virometer for SARS-CoV-2 (Photo courtesy of ICFO)

A portable, low-cost instrument combines a fluorescence reader and microfluidic chip to enable fast, sensitive detection of COVID-19 in saliva samples.

Researchers from the Institute of Photonic Sciences (ICFO Castelldefels, Spain) and IrsiCaixa AIDS Research Institute (Badalona, Spain) have demonstrated a new low-cost portable instrument that manipulates light and fluid for fast and reliable detection of SARS-CoV-2 in saliva samples. Although still in the research stage, the new device could offer a higher sensitivity than today’s COVID-19 rapid antigen tests while also being faster and more cost-effective than PCR tests.

The new instrument, which the researchers call a flow virometry reader, is based on a modification of flow cytometry, a laser-based technique that uses fluorescence to count or analyze cells. Rather than counting cells, the new device detects light emission from fluorescent antibodies that bind to specific viral particles. It can offer quantitative results in less than 30 minutes using an instrument that is about the size of a shoebox. Also, non-specialist users can easily operate the device, and testing can be carried out anywhere since no specialized laboratory is required. To run a test, a saliva sample is introduced in a solution that contains fluorescent antibodies that will attach to SARS-CoV-2 particles. The sample is then processed by the flow virometry reader, which uses a single microfluidic channel to pass the sample through a laser illumination and detection setup. If viral particles are present in the solution, they change the sample’s fluorescence in a detectable way, providing information that can be used to calculate the viral concentration.

The researchers calibrated the new instrument by determining its detection limits using a set of prepared saliva samples containing a known amount of virus. They then evaluated the performance of the system for detecting SARS-CoV-2 in clinical samples. For this, they conducted a blind test of frozen saliva samples from more than 50 COVID-19 positive and uninfected individuals. The instrument reliably detected 31 out of 34 COVID-19 positive patient samples and 18 out of 20 SARS-CoV-2 negative samples, which had been previously analyzed using PCR testing.

While the proposed technology has the potential to replace or complement PCR tests, more experiments are necessary to clinically assess the similarity of the two methods. The researchers are now working to develop an integrated flow virometry reader for simultaneous SARS-CoV-2 antigen and antibody analysis. Such a testing device could identify active infections as well as provide information on the immune response to a previous infection or vaccination. This will allow fast checking of vaccine efficiency and help to determine whether additional vaccination boosters are needed. Before moving into the commercialization phase, the researchers will perform a series of additional tests to increase the statistics and the specificity of the device.

“Our instrument, which requires just a few drops of saliva, would be useful for mass screening in settings such as restaurants, schools, offices, theatres and cinemas,” said researcher Alfredo Ongaro from ICFO. “What’s more, the technology can be easily adapted to detect markers for other pathogens, including those that may be involved in future outbreaks.”

Related Links:
ICFO 
IrsiCaixa AIDS Research Institute 

Gold Member
SARS‑CoV‑2/Flu A/Flu B/RSV Sample-To-Answer Test
SARS‑CoV‑2/Flu A/Flu B/RSV Cartridge (CE-IVD)
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Chagas Disease Test
LIAISON Chagas
New
FOB+Transferrin+Calprotectin+Lactoferrin Test
CerTest FOB+Transferrin+Calprotectin+Lactoferrin Combo Test

Print article

Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: The HIV-1 self-testing chip will be capable of selectively detecting HIV in whole blood samples (Photo courtesy of Shutterstock)

Disposable Microchip Technology Could Selectively Detect HIV in Whole Blood Samples

As of the end of 2023, approximately 40 million people globally were living with HIV, and around 630,000 individuals died from AIDS-related illnesses that same year. Despite a substantial decline in deaths... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.